...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Treatment for cirrhotic ascites
【24h】

Treatment for cirrhotic ascites

机译：治疗肝硬化腹水

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Common complications of decompensated liver cirrhosis are esophageal varices, hepatic encephalopathy and ascites. After the onset of complications, the prognosis worsens. In patients with ascites, the 5-year mortality rate is 44%. Furthermore, hyponatremia, spontaneous bacterial translocation and hepatorenal syndrome also greatly worsen the prognosis. Effective treatment of cirrhotic ascites improves the quality of life and survival rate. Recently, the newly produced diuretic, tolvaptan (vasopressin V2 receptor antagonist), was reported to be effective in the treatment of refractory ascites in liver cirrhosis; however, there has not been an associated positive effect on the prognosis. There are various types of treatment for ascites, such as large-volume paracenteses, a cell-free and concentrated ascites reinfusion therapy, a transjugular intrahepatic portosystemic shunt, and a peritoneo-venous shunt. Although they improve the prognosis, liver transplantation remains the ultimate form of treatment. The present article discusses the therapeutic management of cirrhotic ascites.
机译：常见的肝脏失代偿性的并发症肝硬化食管静脉曲张,肝脑病和腹水。并发症,预后恶化。腹水,5年死亡率是44%。此外,低钠血症,自发的细菌易位和肝肾综合征大大恶化了预后。肝硬化腹水的提高了生活的质量和存活率。利尿剂,tolvaptan(抗利尿激素V2受体拮抗剂),据报道是有效的治疗难治性腹水的肝脏肝硬化;积极的影响预后有关。有各种类型的治疗腹水,如大型paracenteses概况、读和集中腹水再输注治疗transjugular肝内门体静脉的分流,和一个peritoneo-venous分流。改善预后,肝移植仍然是治疗的终极形式。本文讨论了治疗肝硬化腹水的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号